These beaten shares could double in the next 5 years
CrisPR Therapeutics has lost momentum in recent years. One product sold by the company has not yet received much revenue. This should change over time, and biotechnology may have been damaged by further clinical victories. 10 shares we like more than CrisPR Therapeutics › Despite the great clinical progress, CRISPR therapy (Nasdaq: CRSP) has fought … Read more